N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide | 1193525-29-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide
• 英文别名: N-[[3-[5-(3-methoxyphenyl)thiophen-2-yl]phenyl]methyl]methanesulfonamide
• CAS: 1193525-29-9
• 化学式: C₁₉H₁₉NO₃S₂
• 分子量: 373.497
• InChiKey: KUXYHIXLMKKUNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以33%的产率得到N-(3-[5-(3-hydroxyphenyl)-2-thienyl]benzyl)methanesulfonamide
  参考文献：
  名称：

  New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity

  摘要：

  17 beta-Hydroxystcroid dehydrogenase type 1 (17 beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ER alpha). Because of the overexpression of 17 beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17 beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17 beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC50 of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17 beta-HSD2, ER alpha) and excellent pharmacokinetic properties after peroral application to rats.

  DOI：

  10.1021/jm901195w
• 作为产物：
  描述：

  (3-甲烷磺酰氨甲基)苯基硼酸 、 2-溴-5-(3-甲氧基苯基)噻吩 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 150.0 ℃ 、1.5 MPa 条件下， 反应 0.25h， 以58%的产率得到N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide
  参考文献：
  名称：

  New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity

  摘要：

  17 beta-Hydroxystcroid dehydrogenase type 1 (17 beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ER alpha). Because of the overexpression of 17 beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17 beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17 beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC50 of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17 beta-HSD2, ER alpha) and excellent pharmacokinetic properties after peroral application to rats.

  DOI：

  10.1021/jm901195w

文献信息

• [EN] SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE LA 17-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：UNIV SAARLAND

  公开号：WO2012025638A1

  公开（公告）日：2012-03-01

  The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.

  这项发明涉及选择性的、非类固醇17β-羟基类固醇脱氢酶1型（17β-HSD1）抑制剂的生产和使用，特别用于治疗和/或预防激素相关疾病。
• SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
  申请人：Universität des Saarlandes

  公开号：EP2609089A1

  公开（公告）日：2013-07-03